Wedbush analyst Robert Driscoll downgraded Surface Oncology (SURF) to Neutral from Outperform after it was announced that Coherus Biosciences (CHRS) will acquire Surface in a stock-for-stock transaction.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SURF:
